MedTrace Logo

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

NCT06693128 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-01-28

No results posted yet for this study

Summary

This study is a multicenter, randomized, uncontrolled clinical trial to evaluate the efficacy and safety of camrelizumab combined with or without apatinib and SOX of neoadjuvant treatment for resectable locally advanced gastric or gastroesophageal junction adenocarcinoma.

Conditions

  • Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions

DRUG

Camrelizumab

Camrelizumab 200mg

DRUG

Apatinib

Apatinib 250mg

DRUG

S-1, Oxaliplatin

S-1, Oxaliplatin, q3w

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Zhenggang Zhu · Ruijin Hospital

  • Yantao Tian · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-21
Primary Completion
2026-05-30
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06693128 on ClinicalTrials.gov